In our ongoing investigation of new compounds with activity against malaria parasites, we tested the in vitro antiplasmodial activity of fractions and purified compounds from Cassia fistula L., a plant traditionally used by native populations of Tanzania, Zimbabwe, Mozambique and Brazil to treat malaria or symptoms associated with this disease. Crude extracts from leaves, bark and fruits were tested for their antiplasmodial activity against the chloroquinesensitive strain of Plasmodium falciparum (D10), where leaf extracts showed the highest activity. The chloroform extract of the leaves was further bioassayguided fractionated using a combination of centrifugal partition chromatography and flash column chromatography. Three main antiplasmodial principles, phytol (1) (IC 50 18.9 ± 0.60 µM), lutein (2) (IC 50 12.5 ± 0.35 µM), and di-lineolylgalactopyranosyl-glycerol (DLGG) (IC 50 5.8 ± 0.27 µM) (3), were isolated and identified using spectroscopic methods. When the three active principles were tested for their cytotoxicity using a Chinese Hamster Ovarian (CHO) cell line, compound 3 showed very weak toxicity (IC 50 75.9 ± 0.28 µM), while the other two compounds were nontoxic, even at the highest concentration tested.
Malaria is the most important infectious disease that affects the poorest populations around the world, with an elevated mortality incidence. There were an estimated 655,000 malaria deaths in 2010 of which 91% were in Africa [1a] . One of the main factors contributing to the escalating prevalence and distribution of malaria is the emergence and spread of drug-resistant parasites, particularly Plasmodium falciparum. Although today artemisinin is the most powerful weapon in the global war against chloroquine-resistant malaria, there are recent concerns that the efficacy of artemisininbased combination therapies has declined on the Thai-Cambodian border, historically a site of emerging antimalarial-drug resistance [1b] . Therefore, there is an urgent need to discover and develop new, effective and safe drugs for the treatment of this disease. Plants represent an important source of novel antimalarial compounds, as represented by quinine and artemisinin. The investigation of species used traditionally to treat malaria has often yielded potentially useful compounds [1c, 1d] .
Cassia fistula L. is an ornamental tree commonly known as the Golden Shower, and it is one of the 400 different species that comprise the genus Cassia (family Caesalpinaceae) [2a] . PROTA (Plant Resources of Tropical Africa) lists C. fistula pods as a plant with historical use to treat malaria [2b] . In Brazil, C. fistula bark, leaves and seeds are used as an adjunct remedy for malaria [2c] . In Tanzania, Zimbabwe, and Mozambique, C. fistula leaves are chewed with milk as a remedy for epilepsy, which traditional healers consider a symptom of malaria [2d] . Other Cassia species with pronounced antimalarial properties are used throughout Africa, for example, C. occidentalis, C.africana, C. floribunda and C. hirsuta. Some of them have been shown to possess in vivo antiplasmodial activities [3a, 3b] . Other important therapeutic applications include their use as a cicatrizant, antipyretic, analgesic, and hypoglycemiant, and also for the treatment of hypercholesterolemia [2a] . C. fistula leaf extract is indicated for its anti-tussive, wound healing, and hepatoprotective properties [4a-4c] . It was also reported that the methanol extract of C. fistula had strong larvicidal and ovicidal activity against the filarial and malarial vector mosquitoes [4d]. Thus, C. fistula is well anchored in its traditional uses and has now found widespread acceptance across the world.
C. fistula fruits and stem bark, but not the leaves, were originally screened by Spencer and co-workers [5] during the World War II era in an effort to identify candidates with antimalarial activity. Their results showed that a chloroform extract of the fruit showed moderate activity when administered orally to Plasmodium gallinaceum sporozite infected chicks. In our ongoing investigation of plants used for the treatment of malaria [6a-6e], we report the extraction and bioassay of extracts from bark, fruit and leaves of C. fistula against the chloroquine-sensitive strain (D10) of Plasmodium falciparum. We followed this by bioassay-guided fractionation of the leaf extract, the most active plant part, which led to the isolation of three compounds with antiplasmodial activity. The toxicity of these compounds was evaluated in a Chinese Hamster Ovarian cell line (CHO). A general protocol was initially applied for extraction of C. fistula bark, fruit and leaves to generate four main extracts: L-1 (n-hexane), L-2 (CHCl 3 ), L-3 (CHCl 3, basic) and L-4 (aqueous). The four extracts were tested for their in vitro antiplasmodial activity against the chloroquine sensitive strain (D10) of P. falciparum. Results showed that both L-2 and L-3 from the leaves, and L-3 from the bark showed the highest activity (IC 50 12.3, 14.57 and 13.4 µg/mL, respectively) ( Table 1) . We proceeded with bioassay-guided fractionation of the L-2 extract from the leaves.
In order to determine the antiplasmodial principles in the chloroform leaf extract (L-2), we followed an isolation scheme which, at every step, monitored and assessed the in vitro antiplasmodial activity of the resulting fractions ( Figure 1 and L-1 to L-4 were produced by successive extraction, L-1: n-hexane, L-2: chloroform, L-3: basic chloroform and L-4: aqueous. 2). Centrifugal partition chromatography generated 7 main fractions, where the most active among them was CPC-6 (IC 50 9.1 µg/mL) ( Figure 1 ). This fraction was further fractionated using flash column chromatography to afford 13 fractions. Table 2 shows the results of antiplasmodial activity in terms of parasite survival at three concentrations (20, 10 and 5 µg/mL). Among the 13 fractions, fractions 2, 4, and 10 showed the highest activity. These fractions were further purified to afford the three active compounds 1, 2 and 3. Their antiplasmodial and cytotoxic activities were determined (Table 3) .
Compound 1 was identified as the diterpene E-phytol through comprehensive one and two dimensional NMR analysis, GC-MS analysis (EI), and comparison with published data [7a] . E-phytol showed an in vitro antiplasmodial activity of 5.6 ± 0.18 µg/mL against the chloroquine sensitive strain (D10) of Plasmodium falciparum. E-phytol has been identified as one of two compounds responsible for the antiplasmodial activity of the ethnobotanical plant Microglossa pyrifolia, through bioassay-guided fraction against two the strains; chloroquine resistant PoW and chloroquine sensitive Dd2 of P. falciparum, with activity of 2.5 and 3.4 µg/mL, respectively. The other compound was a structurally related principle named 6-E-gerenylgeraneol-19-oic acid [7b].
Compound 2 was identified as the carotenoid lutein through its one and two dimensional NMR analysis, its HRESI-MS, with m/z 568.4225, [M+H] + , corresponding to C 40 H 56 O 2 , and by comparison with reported data [8] and a reference sample (Chromadex Irvine, CA). Lutein showed an in vitro antiplasmodial activity at 7.1 ± 0.20 µg/mL. This compound has never been known for this activity, but it was reported that it has an antimicrobial activity, where it inhibited the growth of Enterococcus faecium bacteria at very low concentrations (MIC 8.0 µg/mL) [8] . This is the first report to identify this compound in C. fistula, and to determine its antiplasmodial activity.
Compound 3 was identified as the galactolipid 1, Figure 2 ). Optical rotation, TLC and NMR data matched well with published data for this compound [9a, 9b] . DLGG showed the highest antiplasmodial activity among the three identified compounds (IC 50 4.5 ± 0.18 µg/mL). This is the first report to assess the antiplasmodial activity of DLGG. Other related glycolipids have been reported, through the bioassay-guided fractionation technique, with strong antiplasmodial activity [9c]. These amphiphilic compounds can be incorporated into the lipid bilayer of the erythrocyte membrane irreversibly and can induce shape transformation of this membrane [9d]. Thus the inhibition of parasite growth observed in vitro could be attributed to indirect effects due to stomatocytic echinocytic modifications of the host cell membrane [9c]. A glycolipid, α-GalCer derived from a marine sponge extract, and also its synthesized N-C-analogue showed an inhibitory activity against the liver stages of the rodent malaria parasite P. yoelii. A multifactorial mechanism of action was hypothesized [9e]. This is the first report of compounds 1-3 in C. fistula, and the determination of the antiplasmodial activity of 2 &3.
In order to determine the specificity of the antiplasmodial activity of the isolated compounds, they were evaluated for their general cytotoxicity using the Chinese Hamster Ovarian (CHO) cell line. The corresponding selectivity index (SI) values (IC 50 CHO / IC 50 D10) are listed in Table 3 . No observed toxicity was observed for compounds 1 and 2 at the highest concentration tested (100 µg/mL), with SI > 17.7 and > 14.4, respectively. Compound 3 showed weak toxicity (58.8 ± 0.22 µg/mL) with a SI of 13.1 (Table 3 ). The data suggest that the antiplasmodial activity of these three compounds is not likely to be due to general toxicity. The three isolated active compounds collectively constitute about 37% of the parent fraction CPC-6. Results suggest that the antiplasmodial activity of C. fistula leaves, and specifically fraction CPC-6 (IC 50 9.1 µg/mL), can be partially explained by the isolated compounds. The isolated compounds were not as effective as the chloroquine standard compounds and did not achieve the same level of chemosuppression. However, our isolated compounds could be used as scaffolds to generate leads with enhanced antiplasmodial activity, and reduced cytotoxicity. The identification of the antiplasmodial principles from Cassia fistula leaves suggest that they may play a role in the antimalarial properties of this plant.
Experimental
Chemicals and instrumentation: Solvents and reagents were HPLC grade and purchased from Fisher Scientific (Waltham, MA, USA). Centrifugal partition chromatography was performed on an Armen fully integrated CPC spot instrument SCPC 2 × 500 (Armen instrument, St-Ave, France). This instrument is a fully automated system consisting of a CPC column compartment, a pump, an injector, a UV/Vis detector, a fraction collector, a digital screen and a flat PC, and Armen Glider CPC software (Armen instrument, St-Ave, France). Total column volume of this model is 1000 mL (2× 500 mL). Electrospray ionizationion-ion trap-time of flightmass spectrometry (ESI-IT-TOF) was used for compound analysis and formula determination (Shimadzu Scientific Instruments, Columbia, MD). NMR spectra were recorded on a Bruker Avance 600 MHz spectrophotometer (Bruker BioSpin Corporation, Billerica, MA) located in the DHMRI Core Laboratory facility at North Carolina Research Campus, Kannapolis, NC.
Plant material, extraction and preliminary testing: Cassia fistula L. bark, fruit, and leaves were obtained from the Honolulu Botanical Gardens, Hawaii, in November 2009 and kindly identified by Naomi Hoffman, the botanist of the Gardens. A voucher specimen (RG 06) has been deposited in the Chrysler Herbarium (CHRB) at Rutgers University, NJ. Freeze-dried samples (20 g each) from the bark, fruit, and leaves of C. fistula were extracted overnight at room temperature, with n-hexane (3x 100 mL). The n-hexane was evaporated to afford L-1. After filtration, the powdered material was air dried and extracted with 80% MeOH (5 x 100 mL). Organic solvent was evaporated and the remaining aqueous layer was partitioned with CHCl 3 (3x 100 mL) to afford L-2. The aqueous layer was then rendered alkaline with aqueous ammonia solution and re-extracted with CHCl 3 (3 x 100 mL) to afford extract L-3. The remaining aqueous layer from each tissue extraction was freeze-dried to afford the extract L-4. All extracts were tested for their antiplasmodial activity against the chloroquine resistant strain of Plasmodium falciparum (D10). Based on its comparatively higher antiplasmodial activity, leaf extract L-2 was further subjected to bioactivity guided isolation of active components.
Bioactivity-directed isolation of active compounds from C. fistula leaves: Leaves (300 g) were extracted following the same procedure as above to afford 9.5 g, 9.0 g and 0.1 g of L-1, L-2 and L-3, respectively. The L-2 extract was separated by counter current chromatography with a HEMWat (n-hexane: ethyl acetate: methanol: water, 4:1:2:1) solvent system using the upper phase as the stationary phase (descending mode), following the previously reported procedure [6d]. The L-2 extract (1.2 g x 2 runs), dissolved in 30 mL of 1:1 (v/v) mixture of each phase of the solvent system, was injected through the sample loop. The mobile phase was pumped into the inlet of the preparative columns (2 x 500 mL) at a flow rate of 10 mL/min for 150 min and the stationary phase at the same flow rate for another 150 min. The columns speed was set at 1200 rpm and the columns temperature was maintained at 29°C using a chiller. The UV detection was set at 254 nm and fractions eluted in 15 mL tubes were subjected to the TLC test using vanillin /sulfuric acid as a visualizing reagent. Fractions with similar compounds, according to their TLC patterns, were combined to afford 7 fractions (CPC-1 to 7). These were concentrated and dried using a Buchi rotary evaporator and subjected to antiplasmodial activity testing. The fraction with the highest antiplasmodial activity and highest yield (CPC-6, 0.814 g) was further subjected to fractionation. CPC-6 (0.620 g) was separated on a Versa Flash high throughout purification system using spherical silica (VersaPack 23 x 53 mm, 11 g, Supelco, Sigma-Aldrich Co, St. Louis, MO), and gradient elution of n-hexane-chloroform and chloroform-methanol mixtures, collecting 50 mL fractions. Based on TLC profile, similar fractions were pooled together to afford 13 fractions. Fractions were dried before bioactivity testing for their antiplasmodial activity. Most active sub-fractions were subjected to further purification using flash chromatography and elution with varying solvent gradients of n-hexane-CHCl 3 -MeOH. Separation was monitored by TLC using CHCl 3 -MeOH (9:1) as developing solvent and vanillinsulfuric acid as a visualizing reagent, as well as HPLC-UV. Fraction 6-2 afforded compound 1 (66 mg), fraction 6-4 compound 2 (52 mg) and fraction 6-10 compound 3 (109.5 mg).
Antiplasmodial activity:
The in vitro assays were performed as previously described [10] . The test samples were prepared to a 2 mg/mL stock solution in 10% DMSO and sonicated to enhance solubility. Samples were tested as a suspension if not completely dissolved. Stock solutions were stored at -20ºC. Further dilutions were prepared on the day of the experiment. Chloroquine (CQ) was used as the reference drug in all experiments. Fractions were tested at concentrations 20, 10 and 5 µg/mL. CQ was tested at concentrations 30, 15 and 7.5 ng/mL. A full dose-response was performed for pure compounds and active fractions to determine the concentration inhibiting 50% of parasite growth (IC 50 ). Test samples were tested at a starting concentration of 100 μg/mL, which was then serially diluted 2-fold in complete medium to give 10 concentrations; with the lowest concentration being 0.2 μg/mL. The same dilution technique was used for all samples. The highest concentration of solvent that the parasites were exposed to was 0.5%, which was shown to have no measurable effect on parasite viability [10] . The IC 50 values were obtained using a non-linear 1266 Natural Product Communications Vol. 7 (10) 2012 Grace et al.
dose-response curve fitting analysis via Graph Pad Prism v.4.0 software. IC 50 values of pure compounds were given as a mean value with standard deviations of 3 independent experiments performed in triplicate.
Cytotoxicity assay: Isolated compounds were tested for in vitro cytotoxicity against a Chinese Hamster Ovarian (CHO) cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [11] . The CHO cells were cultured in Dulbecos Modified Eagles Medium (DMEM): Hams F-12 medium (1:1) supplemented with 10% heat-inactivated fetal calf serum (FCS) and gentamycin (0.05 µg/mL). Sample preparation was the same as for antiplasmodial testing. The highest concentration of solvent to which the cells were exposed had no measurable effect on the cell viability. Emetine dihydrochloride (Sigma) was used as the positive control in all cases. The initial test concentration of emetine was 100 µg/mL, which was serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, the lowest being 0.001 µg/mL. The same dilution technique was applied to all test samples with an initial concentration of 100 µg/mL to give 5 concentrations, with the lowest being 0.01 µg/mL. The concentration of test samples that inhibits 50% of the cells (IC 50 values) was obtained from dose-response curves, using a non-linear dose-response curve fitting analyses via GraphPad Prism v software. IC 50 values of pure compounds were given as a mean value with standard deviations of 3 independent experiments performed in triplicate.
Supplementary data: NMR spectra of the isolated compounds were deposited as supplementary data, and can be found, in the online version.
